Clinical trials: Virus Diseases
Respiratory Disease
Analysis of Vital Signs in Patients With COVID-19
This project will use data obtained from a proprietary vision-based patient monitoring and management system (OxeVision) for measuring heart rate and respiratory rate which is in clinical use at the Coventry and Warwickshire…
- Trial name
- NCT04927078
- Testing
- Observation of breathing pattern
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Oxehealth Limited
Influenza
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-339851 in healthy subjects.
- Trial name
- NCT03345043
- Testing
- VAL-339851
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2 Infection
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
If a treated cancer patient cannot make antibodies to a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Emergency Use Authorization (EUA) or approved vaccine, their risk for infection and its sequelae are…
- Trial name
- NCT05438498
- Testing
- Evusheld (tixagevimab+cilgavimab) IM or IV
- Where
- 40 sites in United States
- Volunteers
- 550 people
- Sponsor
- MediMergent, LLC
COVID-19
SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)
Randomized, double-blind, placebo-controlled, multicenter phase II clinical study of SHEN211 tablets
- Trial name
- NCT06288893
- Testing
- SHEN211 Tablets
- Where
- China
- Volunteers
- 30 people
- Sponsor
- JKT Biopharma Co., Ltd.
Cold
Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome
Efficacy and Safety of Regan Tangjiang for treating the common cold with wind-heat syndrome: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase 2b Study
- Trial name
- NCT03089138
- Testing
- Regan Tangjiang
- Volunteers
- 120 people
- Sponsor
- Beijing Da-an Bio-technology Co., Ltd.
Healthy
Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a daily oral dose of LHF-535 administered for 14 days to healthy participants.
- Trial name
- NCT03993704
- Testing
- LHF-535
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kineta Inc.
Dengue Virus Infection
Dengvaxia US Pregnancy Registry
The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy
- Trial name
- DNG00044 (NCT04486638)
- Testing
- Dengue Tetravalent Vaccine, Live
- Where
- Puerto Rico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Covid19
Dräger COVID-19 Antigen Test Clinical Performance Study
The study is designed to demonstrate suitability of the Dräger Antigen Test for SARS-CoV-2 detection in clinical nasal specimens.
- Trial name
- NCT04698993
- Testing
- Dräger Antigen Test SARS-CoV-2
- Where
- Germany
- Volunteers
- 388 people
- Sponsor
- Drägerwerk AG & Co. KGaA
Influenza
Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)
This is a randomized, double-blind, active-controlled Phase I clinical trial to evaluate the safety and immunogenicity of Influenza Vaccine (Split Virion), Inactivated (High Dose) developed by Sinovac.
- Trial name
- NCT07737106
- Testing
- Influenza Vaccine (Split Virion), Inactivated (High Dose), Influenza Vaccine (Split Virion), Inactivated
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Post-COVID-19 Condition, Post-COVID Condition
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.
- Conditions
- Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID
- Trial name
- NCT07332338
- Testing
- REGENECYTE®
- Where
- 2 sites in United States
- Sponsor
- StemCyte, Inc.
Healthy Subjects, Infection, Human Immunodeficiency Virus
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01366547
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Poliomyelitis
Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly
The present study intends to investigate the use of fractional doses of sanofi pasteur's IMOVAX Polio injected intradermally. The primary objective will be to demonstrate the non-inferiority of fractional doses of IMOVAX Polio…
- Trial name
- NCT00604058
- Testing
- Inactivated Poliomyelitis vaccine (IMOVAX)
- Where
- Philippines
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chronic Hepatitis C
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug approved by the Food and Drug…
- Trial name
- NCT00120835
- Testing
- valopicitabine, pegylated interferon
- Where
- 3 sites in United States, Puerto Rico
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Infection, Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired…
- Conditions
- Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- TRICOVID (NCT05531149)
- Testing
- Trimodulin
- Where
- 64 sites in Argentina, Austria and 12 more
- Volunteers
- 107 people
- Sponsor
- Biotest
COVID-19
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, China. The pathogen was soon identified as a novel coronavirus (SARS-CoV-2), which is closely related to severe acute respiratory…
- Trial name
- NCT05195749
- Testing
- 101-PGC-005 ('005) + SOC
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- 101 Therapeutics
Hepatitis C
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
The purpose of this study is to determine if treatment with Pegylated Interferon Lambda-1a, given in combination with Ribavirin and Daclatasvir for 24 weeks, is as safe and effective as the standard treatment with Pegylated…
- Trial name
- STRUCTURE (NCT01718158)
- Testing
- Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 444 people
- Sponsor
- Bristol-Myers Squibb
RSV Infection
A Study of EDP-323 in Healthy Subjects
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.
- Trial name
- NCT05587478
- Testing
- EDP-323
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatitis C, Chronic
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3…
- Trial name
- NCT02759315
- Testing
- Uprifosbuvir 450 mg, Ruzasvir 60 mg
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19, Upper Respiratory Tract Infections
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours.
- Trial name
- NCT05252468
- Testing
- TaffiX™
- Where
- Bulgaria
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Mycobacterium Avium-Intracellulare Infection, HIV Infections
An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)
To evaluate the efficacy and safety of two doses of azithromycin given chronically for the treatment of Mycobacterium avium bacteremia in AIDS patients.
- Trial name
- NCT00002090
- Testing
- Azithromycin
- Where
- 6 sites in United States
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.